Bay­er's treat­ment for menopause symp­toms hits pri­ma­ry end­points in third late-stage tri­al

Bay­er tout­ed more de­tailed da­ta from a Phase 3 tri­al for elin­zane­tant, a non-hor­mon­al drug can­di­date that it’s in­ves­ti­gat­ing as a treat­ment for menopause symp­toms …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER